On the evening of May 15, Changshan Pharmaceutical announced that a tablet product for treating ed, a wholly-owned subsidiary, had obtained GMP certificate and the product could be put on the market. The workshop certified by GMP certificate is a solid preparation workshop, and the production variety is sildenafil citrate tablets. According to public information, sildenafil citrate is also called Viagra, and its Chinese abbreviation is "Viagra".
Changshan Pharmaceutical announced that according to statistics, "the number of ED patients in China is about 654.38+0.4 billion". Assuming that 30% of them are treated, the number will reach 42 million. Assuming that the ed patients treated each year can take drugs for many times, the potential market size in China is expected to reach10 billion yuan, and the market space is broad.
In this regard, the Shenzhen Stock Exchange sent an inquiry letter to Changshan Pharmaceutical on May 16, asking it to explain the source and accuracy of the data and fully prompt the market risks faced by the company's products. Changshan Pharmaceutical issued a supplementary announcement, saying that the data was retrieved by the staff through the Internet and extracted from some brokerage research reports, and the data source, calculation method and accuracy were not verified.
However, after the announcement that "65438+400 million men in China can't do it" was released, Changshan Pharmaceutical was warmly welcomed, and its share price went up and down continuously on May 16 and May 17, with a cumulative increase of 20.56%.
Then, on the evening of May 17, Changshan Pharmaceutical announced that four senior executives Gao Shuhua, Gao, Ding and the company reduced their holdings of10.008 million shares on the same day, and the amount of reduction exceeded 87.64 million yuan. Changshan Pharmaceutical 20 17 Performance Express shows that Gaoshu Huawei Company is the controlling shareholder, actual controller, chairman and general manager, holding 36.45438+0%; Ding is the director and deputy general manager of the company, and Gao is one of the founders of the company.
After the above-mentioned series of operations, on May 18, Shenzhen Stock Exchange said that Changshan Pharmaceutical's new skin was suspected of violating relevant regulations, and Gao Shuhua and Ding reduced their holdings within two trading days after the company disclosed major events that had a great impact on the stock price. Suspected of violating the relevant provisions of the Guidelines for the Standardized Operation of Listed Companies on the Growth Enterprise Market, disciplinary procedures have been initiated against Changshan Pharmaceutical and related parties.